Lung cancer

5 currently open clinical trials

Osimertinib and bevacizumab versus osimertinib alone for patients with non-small cell lung cancer
ETOP BOOSTER
Anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with lung cancer
EORTC PEARLS
Dosage of a new targeted drug for the treatment of lung cancer
SAKK 19/16
Durvalumab in patients with advanced lung cancer and poor general state of health
SAKK 19/17
Single arm phase II trial evaluating the activity of Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC
ETOP ALERT
All cancer types